BioStar is a site for asking, answering and discussing bioinformatics questions and issues. We are members of the community and find it very useful. Often questions and answers arise at BioStar that are germane to our readers (end users of genomics resources). Every Thursday we will be highlighting one of those items or discussions here in this thread. You can ask questions in this thread, or you can always join in at BioStar.
This week’s highlighted Biostar item is an incarnation of the 23andMe drama. I’ve seen people take on the legal, medical practice, and social aspects. But this thread takes on the underlying bioinformatics as an issue. I thought that was interesting.
Forum: FDA sends a warning letter to 23andMe – Personal Genomics Service marketing to be discontinued
There has been an interesting development in the world of personal genomics. The FDA sent what may be interpreted a cease and desists order:
Therefore, 23andMe must immediately discontinue marketing the Personal Genome Service (PGS) until such time as it receives FDA marketing authorization for the device.
This seems to put bioinformaticians at the forefront of deciding what constitutes credible evidence that the PGS does indeed work as advertised.
I added my favorite additional pieces over there, which haven’t got much airplay among the genoscenti. But go have a look at the wider discussion among bioinformatics practitioners, which I thought was interesting.